Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (AORT) pioneers life-saving medical devices for aortic disease treatment, serving cardiac and vascular specialists worldwide. This dedicated news hub provides investors and medical professionals with timely updates on company developments, clinical advancements, and strategic initiatives.
Access official press releases, earnings reports, and regulatory updates in one centralized location. Track innovations across Artivion's core product lines including aortic stent grafts, surgical sealants, and implantable tissues. Our curated news collection helps stakeholders monitor clinical trial progress, partnership announcements, and market expansion efforts.
Key updates include FDA clearances, international regulatory milestones, and peer-reviewed study results from ongoing trials. Discover how Artivion's technologies continue to reshape treatment protocols in complex cardiovascular surgeries through verified clinical outcomes and surgeon testimonials.
Bookmark this page for continuous access to verified information about AORT's medical advancements. Check regularly for new developments impacting the future of aortic disease management and surgical innovation.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery solutions, announced that it will release its first quarter 2023 financial results on May 4, 2023, post-market. A teleconference call and live webcast will follow at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin. Investors can access the teleconference by dialing 862-298-0702. The replay will be available within an hour post-event. This announcement emphasizes Artivion's ongoing commitment to transparency with its stakeholders regarding its financial performance. The company's innovative product lines, including aortic stent grafts and surgical sealants, aim to address complex cardiac challenges, positioning Artivion within the competitive landscape of over 100 countries globally.
Artivion, Inc. (NYSE: AORT) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 18, 2023 at 8:45 a.m. ET. The company's virtual fireside chat will focus on advancements in cardiac and vascular surgery for aortic diseases.
A live webcast will be available on Artivion's website, with an archived version accessible for 90 days. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for cardiac and vascular surgeons, offering products such as aortic stents, surgical sealants, On-X mechanical heart valves, and implantable human tissues, distributed in over 100 countries.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference. The virtual event is set for March 14, 2023, at 3:20 p.m. ET. A live webcast will be available on Artivion's website, with a 90-day archive post-event. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for aortic disease, offering products like aortic stents, surgical sealants, and On-X mechanical heart valves. The company operates in over 100 countries globally. For more information, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT) reported its fourth quarter and full-year 2022 results. The fourth quarter revenues were $79.4 million, flat year-over-year, but up 5% on a non-GAAP constant currency basis. For the full year, revenues reached $313.8 million, a 5% increase on a GAAP basis. Net income for Q4 2022 was $2.2 million compared to a net loss of $20.1 million in Q4 2021. The company anticipates 2023 revenue growth of 8.0% to 12%, with projected revenues between $331 million and $343 million. A CE mark for BioGlue was received, and confidence was noted for PMA approval for PerClot.
Artivion, Inc. (NYSE: AORT) announced its fourth-quarter and full-year 2022 financial results will be released on February 16, 2023, post-market. The Company will host a teleconference at 4:30 p.m. ET to discuss these results, followed by a Q&A session led by Pat Mackin, Chairman and CEO. Interested parties can listen live by dialing 201-689-8261 or access the webcast through the Artivion website. A replay will be available shortly after the call. Artivion specializes in medical devices for aortic diseases, offering products in over 100 countries.
Artivion, Inc. (NYSE: AORT) announced participation in two investor conferences on November 16 and November 17, 2022. The management team will present at the Stifel 2022 Healthcare Conference on November 16 at 9:10 a.m. ET, with a live webcast available on their website. Additionally, they will hold one-on-one meetings at the Canaccord Genuity MedTech Forum on November 17. Artivion specializes in medical devices for aortic diseases and operates in over 100 countries.
Artivion, Inc. (NYSE: AORT) reported third-quarter 2022 revenue of $76.8 million, marking a 6% increase on a GAAP basis compared to Q3 2021. Non-GAAP constant currency revenue grew by 11%. Notable growth came from On-X, with a 17% GAAP and 19% non-GAAP increase. Internationally, revenue rose by 25% in Asia Pacific and 22% in Latin America. However, the company faced a net loss of $13.7 million compared to a profit in the prior year. The revenue outlook for 2022 has been narrowed to $313.0-$316.0 million, projecting 9%-10% growth. The company also anticipates FDA approvals for key products by year-end.
Artivion, Inc. (NYSE: AORT) has announced that its third quarter 2022 financial results will be released on November 3, 2022, after market close. A teleconference will follow at 4:30 p.m. ET to discuss the results, led by Pat Mackin, the company's CEO. Investors can access the live webcast and replay on Artivion's website.
The company specializes in cardiac and vascular solutions for aortic diseases and sells products in over 100 countries worldwide.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
